Pivots Trading Plans and Risk Controls - Stock Traders Daily
| QURE Stock | USD 5.97 0.05 0.83% |
About 67% of Uniqure NV's investor base is looking to short. The analysis of the overall investor sentiment regarding Uniqure NV suggests that many traders are alarmed. The current market sentiment, together with Uniqure NV's historical and current headlines, can help investors time the market. In addition, many technical investors use Uniqure NV stock news signals to limit their universe of possible portfolio assets.
Uniqure |
Pivots Trading Plans and Risk Controls Stock Traders Daily
Read at news.google.com
 |
Uniqure NV Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Uniqure NV can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Uniqure NV Fundamental Analysis
We analyze Uniqure NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Uniqure NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Uniqure NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Uniqure NV is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Uniqure NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Uniqure NV stock to make a market-neutral strategy. Peer analysis of Uniqure NV could also be used in its relative valuation, which is a method of valuing Uniqure NV by comparing valuation metrics with similar companies.
Peers
Uniqure NV Related Equities
| XFOR | X4 Pharmaceuticals | 11.43 | ||||
| MGTX | MeiraGTx Holdings | 3.36 | ||||
| DAWN | Day One | 1.53 | ||||
| RCKT | Rocket Pharmaceuticals | 1.34 | ||||
| SNDX | Syndax Pharmaceuticals | 1.27 | ||||
| ABOS | Acumen Pharmaceuticals | 0.44 | ||||
| PCVX | Vaxcyte | 0.38 | ||||
| REPL | Replimune | 0.21 | ||||
| SLDB | Solid Biosciences | 0.18 | ||||
| MRUS | Merus BV | 0.29 | ||||
| RYTM | Rhythm Pharmaceuticals | 0.34 | ||||
| INZY | Inozyme Pharma | 0.37 | ||||
| RNA | Avidity Biosciences | 0.69 | ||||
| RGNX | Regenxbio | 0.90 | ||||
| KNSA | Kiniksa Pharmaceuticals | 1.08 | ||||
| PHAT | Phathom Pharmaceuticals | 1.11 | ||||
| STRO | Sutro Biopharma | 1.49 | ||||
| TERN | Terns Pharmaceuticals | 1.58 | ||||
| GPCR | Structure Therapeutics | 1.78 | ||||
| PTGX | Protagonist Therapeutics | 2.56 | ||||
| AMLX | Amylyx Pharmaceuticals | 3.48 | ||||
| LRMR | Larimar Therapeutics | 4.67 |
Complementary Tools for Uniqure Stock analysis
When running Uniqure NV's price analysis, check to measure Uniqure NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Uniqure NV is operating at the current time. Most of Uniqure NV's value examination focuses on studying past and present price action to predict the probability of Uniqure NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Uniqure NV's price. Additionally, you may evaluate how the addition of Uniqure NV to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |